Healthcare Industry News: LifeCycle Pharma
News Release - September 18, 2008
Dr. Michael Beckert Steps Down as EVP and CMO of LifeCycle Pharma Effective December 31, 2008Dr. Karin Hamberg Will Assume Responsibility of Clinical, Regulatory & Medical Affairs
HORSHOLM, Denmark--(HSMN NewsFeed)--LifeCycle Pharma A/S (OMX:LCP) announced today that Dr. Michael Beckert has decided to resign as EVP and CMO of LifeCycle Pharma in order to pursue other opportunities outside LCP effective December 31, 2008. Dr. Karin Hamberg, who is currently EVP of Drug Delivery Research and Alliance & Project Management, will assume responsibility for Clinical, Regulatory, and Medical Affairs undertaking Dr. Beckert’s responsibilities. Dr. Hamberg will be registered with the Danish Commerce and Companies Agency as member of the management board.
“We regret Dr. Beckert’s decision to leave LifeCycle Pharma. At the same time, I would like to thank Dr. Beckert for his significant contributions to the Company. Under his tenure, LifeCycle Pharma has efficiently built an international clinical, regulatory and medical group in Denmark and the U.S. for the upcoming Phase III programs,” says Dr. Claus Braestrup.
“Under Dr. Michael Beckert’s tenure, LifeCycle Pharma achieved approval of its first product, Fenoglide, by the US Food and Drug Administration (FDA) in 2007, and subsequently, it was launched in the US in February 2008 via our partner, Sciele Pharma. Furthermore, Dr. Beckert brought LifeCycle Pharma’s two lead candidates, LCP-Tacro, a once-daily dosage formulation of tacrolimus for immunosuppression treatment, and LCP-AtorFen, a combination product of atorvastatin and fenofibrate for lipid-lowering treatment, through Phase II, including preparation for Phase III which is expected to be initiated before the end of 2008,” Dr. Braestrup elaborates.
“It was a very difficult decision for me,” says Michael Beckert, “however, after more than 4 years, it is time to think ahead and very personal reasons were leading to the decision to leave LifeCycle Pharma as Chief Medical Officer. I am proud of what we have accomplished during this period, and I am looking forward to supporting LCP in the future in the role as a Consultant.”
Dr. Hamberg who serves as EVP currently responsible for Drug Delivery Research and Alliance & Project Management will assume responsibility of Clinical, Regulatory, and Medical Affairs.
Prior to joining LCP, Dr. Hamberg served as Vice President of Development at LEO Pharma A/S, where she held various management positions within Development and R&D Project Management for the past 15 years. Mrs. Hamberg obtained her Medical Degree from University of Copenhagen and holds several diplomas including a Swiss Diploma in Pharmaceutical Medicine.
“I am very pleased to announce that Karin will take responsibility of clinical, regulatory and medical affairs” said Dr. Claus Braestrup. “We are in an exciting stage of development, and we are very much looking forward to utilizing Karin’s knowledge and experience in collaboration with those of our other experienced executive team members within the company.”
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, FenoglideTM, currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.
Source: LifeCycle Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.